STAT Plus: How Gilead’s remdesivir price could come back to haunt the drug industry
ULRICH PERREY/POOL/AFP VIA GETTY IMAGES
In picking a price for the Covid-19 drug remdesivir, Gilead said it was prioritizing “broad and equitable access” over company profits.
No hay comentarios:
Publicar un comentario